perma20160401

(Amounts in Thousands, Except for Share and per Share Amounts)	March 31, 2016			December 31, 2015

ASSETS
Current assets:
Cash	$	798		$	1,435
Restricted cash		—			99
Accounts receivable, net of allowance for doubtful accounts of $1,482 and $1,474, respectively		8,522			9,673
Unbilled receivables - current		3,151			4,569
Inventories		374			377
Prepaid and other assets		3,546			3,929
Current assets related to discontinued operations		29			34
Total current assets		16,420			20,116

Property and equipment:
Buildings and land		20,211			20,209
Equipment		35,200			35,191
Vehicles		417			422
Leasehold improvements		11,626			11,626
Office furniture and equipment		1,755			1,755
Construction-in-progress		488			497
		69,697			69,700
Less accumulated depreciation		(50,484	)		(49,707	)
Net property and equipment		19,213			19,993

Property and equipment related to discontinued operations		531			531

Intangibles and other long term assets:
Permits		16,759			16,761
Other intangible assets - net		1,985			2,066
Unbilled receivables – non-current		296			707
Finite risk sinking fund		21,396			21,380
Other assets		1,342			1,359
Total assets	$	77,942		$	82,913

The accompanying notes are an integral part of these consolidated financial statements.

(Amounts in Thousands, Except for Share and per Share Amounts)	March 31, 2016			December 31, 2015

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,729		$	6,109
Accrued expenses		4,250			4,341
Disposal/transportation accrual		1,473			1,107
Deferred revenue		2,359			2,631
Current portion of long-term debt		1,212			1,481
Current portion of long-term debt - related party		596			950
Current liabilities related to discontinued operations		526			531
Total current liabilities		16,145			17,150

Accrued closure costs		5,286			5,301
Other long-term liabilities		883			867
Deferred tax liabilities		5,460			5,424
Long-term debt, less current portion		7,297			7,405
Long-term liabilities related to discontinued operations		1,047			1,064
Total long-term liabilities		19,973			20,061

Total liabilities		36,118			37,211

Commitments and Contingencies (Note 7)

Series B Preferred Stock of subsidiary, $1.00 par value; 1,467,396 shares authorized, 1,284,730 shares issued and outstanding, liquidation value $1.00 per share plus accrued and unpaid dividends of $883 and $867, respectively		1,285			1,285

Stockholders' Equity:
Preferred Stock, $.001 par value; 2,000,000 shares authorized, no shares issued and outstanding		—			—
Common Stock, $.001 par value; 30,000,000 shares authorized; 11,565,586 and 11,551,232 shares issued, respectively; 11,557,944 and 11,543,590 shares outstanding, respectively		11			11
Additional paid-in capital		105,639			105,556
Accumulated deficit		(64,648	)		(60,808	)
Accumulated other comprehensive loss		(65	)		(117	)
Less Common Stock in treasury, at cost; 7,642 shares		(88	)		(88	)
Total Perma-Fix Environmental Services, Inc. stockholders' equity		40,849			44,554
Non-controlling interest		(310	)		(137	)
Total stockholders' equity		40,539			44,417

Total liabilities and stockholders' equity	$	77,942		$	82,913

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months Ended March 31,
(Amounts in Thousands, Except for Per Share Amounts)	2016			2015

Net revenues	$	10,038		$	13,600
Cost of goods sold		10,004			12,122
Gross profit		34			1,478

Selling, general and administrative expenses		3,055			2,846
Research and development		575			429
Loss on disposal of property and equipment		5			—
Loss from operations		(3,601	)		(1,797	)

Other income (expense):
Interest income		16			8
Interest expense		(168	)		(126	)
Interest expense-financing fees		(57	)		(58	)
Foreign currency loss		—			(5	)
Loss from continuing operations before taxes		(3,810	)		(1,978	)
Income tax expense		36			36
Loss from continuing operations, net of taxes		(3,846	)		(2,014	)

Loss from discontinued operations		(167	)		(223	)
Net loss		(4,013	)		(2,237	)

Net loss attributable to non-controlling interest		(173	)		(172	)

Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(3,840	)	$	(2,065	)

Net loss per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic and diluted:

Continuing operations	$	(.32	)	$	(.16	)
Discontinued operations		(.01	)		(.02	)
Net loss per common share	$	(.33	)	$	(.18	)


Number of common shares used in computing net loss per share:
Basic		11,557			11,486
Diluted		11,557			11,486

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Common Stock						Additional				Common Stock			Accumulated Other				Non- controlling						Total
(Amounts in thousands, except for share amounts)	Shares			Amount			Paid-In Capital				Held In Treasury			Comprehensive (Loss) Income				Interest in Subsidiary			Accumulated Deficit			Stockholders' Equity

Balance at December 31, 2015		11,551,232		$	11		$	105,556			$	(88	)	$	(117	)		$	(137	)	$	(60,808	)	$	44,417
Net loss		—			—			—				—			—				(173	)		(3,840	)		(4,013	)
Foreign currency translation		—			—			—				—			52				—			—			52
Issuance of Common Stock for services		14,354			—			55				—			—				—			—			55
Stock-Based Compensation		—			—			28				—			—				—			—			28
Balance at March 31, 2016		11,565,586		$	11		$	105,639			$	(88	)	$	(65	)		$	(310	)	$	(64,648	)	$	40,539

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months Ended March 31,
(Amounts in Thousands)	2016			2015
Cash flows from operating activities:
Net loss	$	(4,013	)	$	(2,237	)
Less: loss from discontinued operations, net of taxes		(167	)		(223	)

Loss from continuing operations, net of taxes		(3,846	)		(2,014	)
Adjustments to reconcile loss from continuing operations to cash provided by (used in) operating activities :
Depreciation and amortization		884			966
Amortization of debt discount		21			22
Deferred tax expense		36			36
Provision (recovery of) bad debt reserves		8			(34	)
Loss on disposal of plant, property, and equipment		5			—
Issuance of common stock for services		55			70
Stock-based compensation		28			33
Changes in operating assets and liabilities of continuing operations
Restricted cash		35			—
Accounts receivable		1,143			(267	)
Unbilled receivables		1,829			(170	)
Prepaid expenses, inventories and other assets		599			(4	)
Accounts payable, accrued expenses and unearned revenue		(546	)		(1,334	)
Cash provided by (used in) continuing operations		251			(2,696	)
Cash used in discontinued operations		(184	)		(232	)
Cash provided by (used in) operating activities		67			(2,928	)

Cash flows from investing activities:
Purchases of property and equipment		(9	)		(121	)
Proceeds from sale of plant, property, and equipment		1			—
Payment to finite risk sinking fund		(16	)		(7	)
Cash used in investing activities		(24	)		(128	)

Cash flows from financing activities:
Repayments of revolving credit borrowings		(13,853	)		(14,263	)
Borrowing on revolving credit		14,022			15,808
Proceeds from issuance of common stock		—			3
Release of proceeds for stock subscription for Perma-Fix Medical S.A. previously held in escrow		64			—
Principal repayments of long term debt		(577	)		(587	)
Principal repayments of long term debt - related party		(375	)		(375	)
Cash (used in) provided by financing activities		(719	)		586

Effect of exchange rate changes on cash		39			(82	)

Decrease in cash		(637	)		(2,552	)
Cash at beginning of period		1,435			3,680
Cash at end of period	$	798		$	1,128

Supplemental disclosure:
Interest paid	$	100		$	132
Income taxes paid		5			10

The accompanying notes are an integral part of these condensed consolidated financial statements.

Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015.

1.	Basis of Presentation

The consolidated condensed financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“the Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the consolidated condensed financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2016.

The Company suggests that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. As disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, the Company determined that the operations of its majority-owned subsidiary, Perma-Fix Medical S.A. (“PF Medical”), which has not generated any revenues as it continues to be primarily in the research and development (“R&D”) stage, meet the definition of a reportable segment in accordance with Accounting Standards Codification (“ASC”) 280, “Segment Reporting.” Accordingly, as detailed on Note 9 – “Operation Segments,” all of the historical numbers presented in the consolidated financial statements have been recast to include the operations of PF Medical as a separate reportable segment (“Medical Segment”).

Reclassification

Certain prior year amounts have been reclassified to conform with the current year presentation.

2.	Summary of Significant Accounting Policies

Our accounting policies are as set forth in the notes to the December 31, 2015 consolidated financial statements referred to above. During the first quarter of 2016, all of the restricted cash previously held in escrow at December 31, 2015 was released. Such amount represented $35,000 held in escrow for our worker’s compensation policy with the remaining representing proceeds held in escrow resulting from stock subscription agreements executed in connection with the sale of common stock by PF Medical in previous years.

Recently Adopted Accounting Standards

In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge asset. It is effective for annual reporting periods beginning after December 15, 2015 (including interim reporting periods), but early adoption is permitted. The Company adopted ASU 2015-03 retroactively in the first quarter of 2016. The adoption of ASU 2015-03 did not have a material impact to the Company’s results of operations, cash flows or financial position. The adoption of ASU 2015-03 resulted in a decrease in prepaid and other assets of approximately $152,000, a decrease in current portion of long-term debt of $27,000, and a decrease in long-term debt, less current portion of $125,000 for the balances as of December 31, 2015 in the accompanying Consolidated Balance Sheets.

Recently Issued Accounting Standards – Not Yet Adopted

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. In July 2015, the FASB deferred the effective date to annual reporting periods beginning after December 15, 2017 (including interim reporting periods within those periods). Early adoption is permitted to the original effective date of periods beginning after December 15, 2016 (including interim reporting periods within those periods). The ASU may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory.” ASU 2015-11 requires that inventory within the scope of this update be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this update do not apply to inventory that is measured using last-in, first-out (“LIFO”) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (“FIFO”) or average cost. For all entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In March 2016, the FASB issued ASU 2016-07, “Investments- Equity Method and Joint Ventures: Simplifying the Transition to the Equity Method of Accounting.” ASU 2016-07 eliminates the requirement to apply the equity method of accounting retrospectively when a reporting entity obtains significant influence over a previously held investment. ASU 2016-07 is effective for interim and annual periods beginning after December 15, 2016. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).” ASU 2016-08 does not change the core principle of the guidance stated in ASU 2014-09; instead, the amendments in this ASU are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and whether an entity reports revenue on a gross or net basis. ASU 2016-08 will have the same effective date and transition requirements as the new revenue standard issued in ASU 2014-09. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements and classification on the statement of cash flows. ASU 2016-07 is effective for interim and annual periods beginning after December 15, 2016. The Company is still evaluating the potential impact of adopting this guidance on our financial statements.

3.	Intangible Assets

The following table summarizes information relating to the Company’s definite-lived intangible assets:

					March 31, 2016							December 31, 2015
	Useful Lives (Years)				Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangibles (amount in thousands)
Patent		8	-	18	$	546	$	(212	)	$	334	$	539	$	(203	)	$	336
Software			3			395		(367	)		28		395		(364	)		31
Customer relationships			12			3,370		(1,747	)		1,623		3,370		(1,671	)		1,699
Permit			10			545		(386	)		159		545		(373	)		172
Total					$	4,856	$	(2,712	)	$	2,144	$	4,849	$	(2,611	)	$	2,238

The intangible assets noted above are amortized on a straight-line basis over their useful lives with the exception of customer relationships which are being amortized using an accelerated method. The Company has only one definite-lived permit that is subject to amortization.

The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets (including the one definite-lived permit):

	Amount
Year	(In thousands)

2016 (remaining)	$	319
2017		373
2018		334
2019		247
2020		221
	$	1,494

Amortization expenses relating to the definite-lived intangible assets as discussed above were $101,000 and $127,000 for the three months ended March 31, 2016 and 2015, respectively.

4.	Capital Stock, Stock Plans and Stock Based Compensation

The Company has certain stock option plans under which it awards incentive and non-qualified stock options to employees, officers, and outside directors. No stock options were granted during the first quarter of 2016 and 2015.

The summary of the Company’s total Stock Option Plans as of March 31, 2016, as compared to March 31, 2015, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan and the 2003 Outside Directors Stock Plan (“2003 Plan”):

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value⁽²⁾
Options outstanding January 1, 2016		218,200	$	7.65
Granted		─		─	
Exercised		─		─
Forfeited/expired		─		─	
Options outstanding end of period ⁽¹⁾		218,200	$	7.65		4.6	$	13,980
Options exercisable at March 31, 2016⁽¹⁾		181,533	$	8.18		4.6	$	13,980
Options exercisable and expected to be vested at March 31, 2016		212,333	$	7.72		4.6	$	13,980

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value⁽²⁾
Options outstanding Janury 1, 2015		239,023		$	7.81
Granted		─			─	
Exercised		(1,257	)		2.79			$	2,043
Forfeited/expired		(15,000	)		7.10	
Options outstanding end of period ⁽¹⁾		222,766			7.89		5.0	$	22,616
Options exercisable at March 31, 2015⁽¹⁾		167,766		$	8.84		4.9	$	22,616
Options exercisable and expected to be vested at March 31, 2015		213,966		$	8.01		5.0	$	22,616

⁽¹⁾Options with exercise prices ranging from $2.79 to $14.75

⁽²⁾The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the option.

The following table summarizes stock-based compensation recognized for the three months ended March 31, 2016 and 2015 for our employee and director stock options.

Stock Options	Three Months Ended March 31,
	2016		2015
Employee Stock Options	$	13,000	$	13,000
Director Stock Options		15,000		20,000
Total	$	28,000	$	33,000

As of March 31, 2016, the Company has approximately $59,000 of total unrecognized compensation cost related to unvested options, of which $40,000 is expected to be recognized in remaining 2016, with the remaining $19,000 in 2017.

During the three months ended March 31, 2016, the Company issued a total of 14,354 shares of our Common Stock under the 2003 Plan to our outside directors as compensation for serving on our Board of Directors. The Company has recorded approximately $60,000 in compensation expenses (included in selling, general and administration expenses) in connection with the issuance of these shares of our Common Stock to our outside directors.

5.	Loss Per Share

Basic loss per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted loss per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive earnings per shares. The following table reconciles the loss and average share amounts used to compute both basic and diluted loss per share:

	Three Months Ended March 31, (Unaudited)
(Amounts in Thousands, Except for Per Share Amounts)	2016			2015
Net loss attributable to Perma-Fix Environmental Services, Inc., common stockholders:
Loss from continuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(3,673	)	$	(1,842	)
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders		(167	)		(223	)
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(3,840	)	$	(2,065	)

Basic loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(.33	)	$	(.18	)

Diluted loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	(.33	)	$	(.18	)

Weighted average shares outstanding:
Basic weighted average shares outstanding		11,557			11,486
Add: dilutive effect of stock options		—			—
Add: dilutive effect of warrants		—			—
Diluted weighted average shares outstanding		11,557			11,486


Potential shares excluded from above weighted average share calcualtions due to their anti-dilutive effect include:
Stock options

183

186

6.	Long Term Debt

Long-term debt consists of the following at March 31, 2016 and December 31, 2015:

(Amounts in Thousands)	March 31, 2016			December 31, 2015
Revolving Credit facility dated October 31, 2011, as amended, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, variable interest paid monthly at option of prime rate (3.50% at March 31, 2016) plus 1.75% or London Interbank Offer Rate ("LIBOR") plus 2.75%, balance due March 24, 2021. Effective interest rate for first quarter of 2016 was 4.6%. ^{(1) (2)}	$	2,518		$	2,349
Term Loan dated October 31, 2011, as amended, payable in equal monthly installments of principal of $190, balance due on March 24, 2021, variable interest paid monthly at option of prime rate plus 2.25% or LIBOR plus 3.25%. Effective interest rate for first quarter of 2016 was 3.6%. ^{(1) (2)}		5,974	⁽⁵⁾		6,514	⁽⁵⁾
Promissory Note dated August 2, 2013, payable in twelve monthly installments of interest only, starting September 1, 2013 followed with twenty-four monthly installments of $125 in principal plus accrued interest. Interest accrues at annual rate of 2.99%. ^{(3) (4)}		596			950
Capital lease (interest at rate of 6.0%)		17			23
		9,105			9,836
Less current portion of long-term debt		1,808			2,431
Long-term debt	$	7,297		$	7,405

⁽¹⁾Our Revolving Credit facility is collateralized by our accounts receivable and our Term Loan is collateralized by our property, plant, and equipment.

⁽²⁾See below “Revolving Credit and Term Loan Agreement” for payment interest options prior to March 24, 2016. Effective April 1, 2016, the monthly installment payment under the Term Loan became $101,600 as a result of the March 24, 2016 amendment to the loan agreement as discussed below.

⁽³⁾Uncollateralized note.

⁽⁴⁾Net of debt discount of ($29,000) and ($50,000) at March 31, 2016 and December 31, 2015, respectively. See “Promissory Notes and Installment Agreements” below for additional information.

⁽⁵⁾Net of debt issuance costs of ($121,000) and ($152,000) at March 31, 2016 and December 31, 2015, respectively.

Revolving Credit and Term Loan Agreement

The Company entered into an Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated October 31, 2011 (“Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The Loan Agreement, as subsequently amended (“Amended Loan Agreement”), provided the Company with the following Credit Facility: (a) up to $12,000,000 revolving credit (“Revolving Credit”), subject to the amount of borrowings based on a percentage of eligible receivables (as defined) and (b) a term loan (“Term Loan”) of $16,000,000, which required monthly installments of approximately $190,000 (based on a seven-year amortization).

Under the Amended Loan Agreement, the Company had the option of paying an annual rate of interest due on the Revolving Credit at prime plus 2% or London Inter Bank Offer Rate (“LIBOR”) plus 3% and the Term Loan at prime plus 2.5% or LIBOR plus 3.5%.

On March 24, 2016, the Company entered into an amendment to the Amended Loan Agreement with PNC which provided, among other things, the following (the amendment, together with the Amended Loan Agreement is collectively known as the “Revised Loan Agreement”):

●

extended the due date of our Credit Facility from October 31, 2016 to March 24, 2021 (“maturity date”);

●

amended the Term loan to approximately $6,100,000, which requires monthly payments of $101,600 (based on a five-year amortization) and which approximated the term loan balance under the existing Credit Facility at the date of the amendment. The revolving line of credit remains at up to $12,000,000 (subject to the amount of borrowings based on a percentage of eligible receivables as previously defined under the Amended Loan Agreement);

●

released $1,000,000 of the $1,500,000 borrowing availability restriction that the lender had previously placed on the Company in connection with the insurance settlement proceeds received on July 28, 2014 by our PFSG facility, which suffered a fire in 2013. The Company’s lender had authorized the Company to use such proceeds for working capital purposes but had placed an indefinite reduction on our borrowing availability of $1,500,000;

●

revised the interest payment options to paying an annual rate of interest due on the Revolving Credit at prime plus 1.75% or LIBOR plus 2.75% and the Term Loan at prime plus 2.25% or LIBOR plus 3.25%; and

●

revised our annual capital spending maximum limit from $6,000,000 to $3,000,000.

In connection with the amendment, the Company paid PNC a closing fee of $70,000. As a result of the amendment dated March 24, 2016, the Company recorded approximately $68,000 in loss on extinguishment of debt in accordance with ASC 470-50, “Debt – Modifications and Extinguishments,” which has been included in interest expense in the accompanying Consolidated Statements of Operations.

Pursuant to the amendment, the Company may terminate the Revised Loan Agreement upon 90 days’ prior written notice upon payment in full of its obligations under the Revised Loan Agreement. The Company has agreed to pay PNC 1.0% of the total financing in the event the Company pays off its obligations on or before March 23, 2017, .50% of the total financing if the Company pays off its obligations after March 23, 2017 but prior to or on March 23, 2018, and .25% of the total financing if the Company pays off its obligations after March 23, 2018 but prior to or on March 23, 2019. No early termination fee shall apply if the Company pays off its obligations after March 23, 2019.

All other terms of the Amended Loan Agreement remain principally unchanged.

As of March 31, 2016, the availability under our revolving credit was $2,740,000, based on our eligible receivables and includes the remaining indefinite reduction of borrowing availability of $500,000 as discussed above.

The Company’s Credit Facility with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our Credit Facility allowing our lender to immediately require the repayment of all outstanding debt under our Credit Facility and terminate all commitments to extend further credit. The Company met its quarterly financial covenants in the first quarter of 2016 with the exception of its minimum quarterly fixed charge coverage ratio requirement of 1.15:1. The Company has obtained a waiver from its lender for this non-compliance (see Note 11- “Subsequent Events – Credit Facility”). The Company expects to meet its quarterly financial covenants in each of the remaining quarters of 2016.

Promissory Note

The Company entered into a $3,000,000 loan dated August 2, 2013 with Messrs. Robert Ferguson and William Lampson (each known as the “Lender”). As consideration for the Company receiving the loan, the Company issued to each Lender a Warrant to purchase up to 35,000 shares of the Company’s Common at an exercise price of $2.23 per share. The Warrants expire on August 2, 2016. As further consideration for the loan, the Company also issued to each Lender 45,000 shares of the Company’s Common Stock. The fair value of the Warrants and Common Stock and the related closing fees incurred from this transaction were recorded as a debt discount, which is being amortized using the effective interest method over the term of the loan as interest expense – financing fees.

7.	Commitments and Contingencies

Hazardous Waste

In connection with our waste management services, we process both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required, we could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.

Legal Matters

In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that would have a material adverse effect on our financial position, liquidity or results of future operations.

Insurance

The Company has a 25-year finite risk insurance policy entered into in June 2003 with American International Group, Inc. (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The policy, as amended, provides for a maximum allowable coverage of $39,000,000 and has available capacity to allow for annual inflation and other performance and surety bond requirements. All of the required payments for this finite risk insurance policy, as amended, have been made by the Company. As of March 31, 2016, our financial assurance coverage amount under this policy totaled approximately $38,874,000. The Company has recorded $15,474,000 in sinking fund related to this policy in other long term assets on the accompanying Consolidated Balance Sheets, which includes interest earned of $1,003,000 on the sinking fund as of March 31, 2016. Interest income for the three months ended March 31, 2016 and 2015 was approximately $14,000 and $6,000, respectively. If the Company so elects, AIG is obligated to pay the Company an amount equal to 100% of the sinking fund account balance in return for complete release of liability from both us and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.

In August 2007, the Company entered into a second finite risk insurance policy for our PFNWR facility with AIG. The policy provided an initial $7,800,000 of financial assurance coverage with an annual growth rate of 1.5%, which at the end of the four year term policy, provides maximum coverage of $8,200,000. The Company has made all of the required payments on this policy. As of March 31, 2016, the Company has recorded $5,922,000 in our sinking fund related to this policy in other long term assets on the accompanying Consolidated Balance Sheets, which includes interest earned of $222,000 on the sinking fund as of March 31, 2016. Interest income for the three months ended March 31, 2016 and 2015 was approximately $2,000 and $1,000, respectively. This policy is renewed annually at the end of the four year term with a nominal fee for the variance between the coverage requirement and the sinking fund balance. The Company has renewed this policy annually from 2011 to 2015 (with fees ranging from $41,000 to $46,000 annually). All other terms of the policy remain substantially unchanged.

Letters of Credit and Bonding Requirements

8.	Discontinued Operations

The Company’s discontinued operations consist of all our subsidiaries included in our Industrial Segment: (1) subsidiaries divested in 2011 and prior, (2) two previously closed locations, and (3) our PFSG facility which suffered a fire and explosion on August 14, 2013 and is currently undergoing closure, subject to regulatory approval.

The Company’s discontinued operations had losses of $167,000 and $223,000 for the three months ended March 31, 2015 and 2014 (net of taxes of $0 for each period). The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. The Company’s discontinued operations had no revenues for each of the periods noted above.

The following table presents the major class of assets of discontinued operations that are classified as held for sale as of March 31, 2016 and December 31, 2015. The asset held for sale is the property which Perma-Fix Michigan, Inc. (“PFMI” – a closed location) formerly operated on (see Note 11- “Subsequent Events – PFMI” for further information on the sale of this property).

(Amounts in Thousands)	March 31, 2016		December 31, 2015

Property	$	450	$	450
Total assets held for sale	$	450	$	450

The following table presents the major classes of assets and liabilities of discontinued operations that are not held for sale as of March 31, 2016 and December 31, 2015:

(Amounts in Thousands)	March 31, 2016		December 31, 2015
Current assets
Other assets	$	29		34
Total current assets		29		34
Long-term assets
Property, plant and equipment, net ⁽¹⁾		81		81
Total long-term assets		81		81
Total assets not held for sale	$	110	$	115
Current liabilities
Accounts payable	$	70	$	85
Accrued expenses and other liabilities		447		437
Environmental liabilities		9		9
Total current liabilities		526		531
Long-term liabilities
Closure liabilities		156		173
Environmental liabilities		891		891
Total long-term liabilities		1,047		1,064
Total liabilities not held for sale	$	1,573	$	1,595

⁽¹⁾net of accumulated depreciation of $10,000 for each period presented.

9.	Operating Segments

In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (a) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.

Our reporting segments are defined as below:

TREATMENT SEGMENT reporting includes:

nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and

R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.

SERVICES SEGMENT, which includes:

On-site waste management services to commercial and government customers;

Technical services, which include:

professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;

integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;

global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers;

Nuclear services, which include:

technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;

remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and

A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.

MEDICAL SEGMENT reporting includes: R&D costs for the new medical isotope production technology from our majority-owned Polish subsidiary, PF Medical. The Medical Segment has not generated any revenue as it continues to be primarily in the R&D stage. All costs incurred for the Medical Segment are reflected within R&D in the accompanying Consolidated Statements of Operations and consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of this new technology.

Our reporting segments exclude our corporate headquarters and our discontinued operations (see Note 8 – “Discontinued Operations”) which do not generate revenues.

The table below presents certain financial information of our operating segments as of and for the three months ended March 31, 2016 and 2015 (in thousands).

Segment Reporting as of and for the Quarter Ended March 31, 2016
	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,204		$	2,834			—		$	10,038		$	—		$	10,038
Intercompany revenues		4			5			—			9			—			—
Gross profit		(138	)		172			—			34			—			34
Research and development		106			26			438			570			5			575
Interest income		—			—			—			—			16			16
Interest expense		(2	)		—			—			(2	)		(166	)		(168	)
Interest expense-financing fees		—			—			—			—			(57	)		(57	)
Depreciation and amortization		713			161			—			874			10			884
Segment loss before income taxes		(1,248	)		(725	)		(438	)		(2,411	)		(1,399	)		(3,810	)
Income tax expense		36			—			—			36			—			36
Segment loss		(1,284	)		(725	)		(438	)		(2,447	)		(1,399	)		(3,846	)
Expenditures for segment assets		8			—			1			9			—			9

Segment Reporting as of and for the Quarter Ended March 31, 2015
	Treatment			Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	9,749		$	3,851			—		$	13,600		$	—		$	13,600
Intercompany revenues		2			8			—			10			—			—
Gross profit		1,235			243			—			1,478			—			1,478
Research and development		34			—			395			429			—			429
Interest income		—			—			—			—			8			8
Interest expense		(22	)		—			—			(22	)		(104	)		(126	)
Interest expense-financing fees		—			—			—			—			(58	)		(58	)
Depreciation and amortization		764			190			—			954			12			966
Segment income (loss) before income taxes		221			(303	)		(395	)		(477	)		(1,501	)		(1,978	)
Income tax expense		36			—			—			36			—			36
Segment income (loss)		185			(303	)		(395	)		(513	)		(1,501	)		(2,014	)
Expenditures for segment assets		104			16			—			120			1			121

⁽¹⁾Amounts reflect the activity for corporate headquarters not included in the segment information.

Certain statements contained within this report may be deemed "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the "Private Securities Litigation Reform Act of 1995"). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words "believe," "expect," "anticipate," "intend," "will," and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,

While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to have been correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:

As disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, the Company determined that the operations of its majority-owned subsidiary, Perma-Fix Medical S.A. (“PF Medical”), which has not generated any revenues as it continues to be primarily in the research and development (“R&D”) stage, meet the definition of a reportable segment in accordance with Accounting Standards Codification (“ASC”) 280, “Segment Reporting.” Accordingly, all of the historical numbers presented in the consolidated financial statements have been recast to include the operations of PF Medical as a separate reportable segment (“Medical Segment”).

Revenue decreased $3,562,000 or 26.2% to $10,038,000 for the three months ended March 31, 2016 from $13,600,000 for the corresponding period of 2015. Revenue from our Treatment Segment decreased $2,545,000 or 26.1% primarily due to both lower averaged price waste and lower volume. Our first quarter 2016 financial results were impacted by the timing of certain large waste treatment shipments that were delayed to later this year. We expect to receive these shipments in the second and/or third quarters. Services Segment revenue decreased $1,017,000 or 26.4% primarily due to the completion of a certain large contract in December 2015 in the nuclear services area. Gross profit decreased $1,444,000 or 97.7% primarily due to reduced revenue. Selling, General, and Administrative (SG&A) expenses increased $209,000 or 7.3% for the three months ended March 31, 2016 as compared to the corresponding period of 2015.

Our Treatment and Services Segments’ business continues to be heavily dependent on services that we provide to governmental clients directly as the contractor or indirectly as a subcontractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including the current economic conditions and the manner in which the government will be required to spend funding to remediate federal sites. In addition, our governmental contracts and subcontracts relating to activities at governmental sites are generally subject to termination or renegotiation on 30 days notice at the government’s option. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows.

Our cash flow requirements for remaining 2016 will consist primarily of general working capital needs, scheduled principal payments on our debt obligations and capital leases, remediation projects and planned capital expenditures which we plan to fund from operations and our Credit Facility availability. Our majority-owned Polish subsidiary, PF Medical, continues to dedicate resources to the R&D of the new medical isotope production technology and to take the necessary steps for eventual submission of this technology for U.S. Food and Drug Administration (“FDA”) and other regulatory approval and commercialization of this technology. We believe that the need for capital by PF Medical will require PF Medical to obtain such capital requirements through obtaining its own credit facility or additional equity raise, which if such equity raise is successful, could dilute our ownership of PF Medical. If PF Medical is unable to raise the necessary capital, PF Medical may be required to reduce, delay or eliminate for a period of time its R&D program.

The reporting of financial results and pertinent discussions are tailored to three reportable segments: The Treatment, Services, and Medical Segments. Our Medical Segment encompasses the operations of our majority-owned Polish subsidiary, PF Medical, which has not generated any revenue and all costs incurred are included within R&D.

Consolidated revenues decreased $3,562,000 for the three months ended March 31, 2016, compared to the three months ended March 31, 2015, as follows:

Treatment Segment revenue decreased $2,545,000 or 26.1% for the three months ended March 31, 2016 over the same period in 2015. The revenue decrease was primarily due to lower revenue generated from government clients of approximately $2,086,000 or 29.6% due to both lower averaged price waste and lower volume. Other nuclear revenue decreased approximately $547,000 primarily due to lower averaged price waste. The Services Segment revenue decrease of $1,017,000 or 26.4% in the three months ended March 31, 2016 from the corresponding period of 2015 was primarily the result of the completion of a certain large project in the nuclear services area in December 2015. This project was awarded to us in the second half of 2014 and had generated revenue of approximately $1,900,000 in the first quarter of 2015.

Cost of goods sold decreased $2,118,000 for the quarter ended March 31, 2016, compared to the quarter ended March 31, 2015, as follows:

Cost of goods sold for the Treatment Segment decreased by $1,172,000 or 13.8% primarily due to lower revenue. We incurred lower disposal, transportation, lab, and material and supplies costs totaling approximately $850,000. Our overall fixed costs were lower by approximately $361,000. Salaries and payroll related expenses were lower by approximately $159,000 and general expenses were lower by approximately $56,000 in various categories as we continue to streamline our costs. Depreciation expense was lower by approximately $49,000 as certain assets became fully depreciated in the latter part of 2015. In addition, maintenance costs were lower by approximately $112,000. In the prior period of 2015, we incurred higher costs in connection with the maintenance of certain buildings and equipment. Services Segment cost of goods sold decreased $946,000 or 26.2% primarily due to the decrease in revenue as discussed above. The decrease in cost of goods sold was primarily in salaries and payroll related, travel, and outside services expenses totaling approximately $817,000. The remaining decrease was in material and supplies of approximately $85,000 and general expenses in various categories totaling approximately $28,000. Included within cost of goods sold is depreciation and amortization expense of $852,000 and $912,000 for the three months ended March 31, 2016, and 2015, respectively.

Gross profit for the quarter ended March 31, 2016 decreased $1,444,000 over the corresponding period of 2015, as follows:

Gross profit decreased primarily due to decreased revenue. Treatment Segment gross profit decreased $1,373,000 or 111.2% and gross margin decreased to (1.9%) from 12.7% primarily due to decreased revenue from both lower averaged price waste and volume and the impact of our fixed costs. In the Services Segment, the decreases in gross profit of $71,000 and gross margin from 6.3% to 6.1% was primarily due to the decrease in revenue as discussed above.

SG&A expenses increased $209,000 for the three months ended March 31, 2016, as compared to the corresponding period for 2015, as follows:

The increase in total SG&A was primarily due to higher SG&A costs in the Services Segment with increased salary expense of approximately $229,000 related to bids and proposal work for potential projects. Outside services expenses were higher by approximately $70,000 resulting from more business/consulting/legal matters. Bad debt expense was higher by approximately $15,000. Treatment SG&A was higher primarily due to higher bad debt expense of approximately $28,000 with the remaining higher expense in marketing costs related to tradeshows. The decrease in administrative SG&A was primarily the result of lower outside services expenses by approximately $163,000 resulting from fewer consulting/business/legal matters. Included in SG&A expenses is depreciation and amortization expense of $32,000 and $54,000 for the three months ended March 31, 2016 and 2015, respectively.

R&D costs increased $146,000 for the three months ended March 31, 2016, as compared to the corresponding period of 2015. Research and development costs consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of new technologies and technological enhancement of new potential waste treatment processes. The increase in R&D costs was primarily in the Treatment and Medical Segments for enhancement of treatment processes and the development of the new medical isotope technology, respectively.

Interest expense increased $42,000 in the first quarter of 2016 as compared to the corresponding period of 2015 primarily due a $68,000 in loss on debt extinguishment (recorded as interest expense) incurred as result of the amendment dated March 24, 2016 that we entered into with our lender which extended the due date of our credit facility, among other things, to March 24, 2021. In addition, interest expense was higher resulting from higher average revolver loan balance over the period. The higher interest expense was partially offset by lower interest on our declining Term Loan balance and lower interest from the declining $3,000,000 loan dated August 2, 2013 (see “Liquidity and Capital Resources – Financing Activities” for the amendment that we entered with our lender on March 24, 2016).

The Company’s discontinued operations consist of all our subsidiaries included in our Industrial Segment: (1) subsidiaries divested in 2011 and prior, (2) two previously closed locations, and (3) our PFSG facility, which is currently undergoing closure, subject to regulatory approval.

We had net losses of $167,000 and $223,000 for our discontinued operations for the three months ended March 31, 2016 and 2015, respectively (net of taxes of $0 for each period). The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. Our discontinued operations had no revenues for each of the periods noted above.

On May 2, 2016, PFMI entered into an Agreement as to the sale of the property which it formerly operated on for a sale price of $450,000. The Agreement provides for a down payment of approximately $75,000 which after certain closing and settlement costs, PFMI received approximately $36,000. The Agreement also provides for, among other things, the balance of the purchase price of $375,000 to be paid by the buyer in 60 equal monthly installment of approximately $7,250, with the first payment due June 15, 2016. PFMI retains legal title to the property until the buyer fulfills the obligations under the Contract except under limited conditions.

Our cash flow requirements during the three months ended March 31, 2016 were primarily financed by our operations and Credit Facility availability. Our majority-owned Polish subsidiary, PF Medical, continues to dedicate resources to the R&D of the new medical isotope production technology and to take the necessary steps for eventual submission of this technology for FDA and other regulatory approval and commercialization of this technology. We believe that the need for capital by PF Medical will require PF Medical to obtain such capital requirements through obtaining its own credit facility or additional equity raise, which if such equity raise is successful, could dilute our ownership of PF Medical. If PF Medical is unable to raise the necessary capital, PF Medical may be required to reduce, delay or eliminate for a period of time its R&D program. We continue to explore all sources of increasing revenue. We are continually reviewing operating costs and are committed to further reducing operating costs to bring them in line with revenue levels, when necessary. Our capital requirements consist of general working capital needs, scheduled principal payments on our debt obligations, remediation projects and planned capital expenditures. Although there are no assurances, we believe that our cash flows from operations and our available liquidity from our Credit Facility are sufficient to fund our Treatment and Services Segment operations.

The following table reflects the cash flow activities during the first three months of 2016:

As of March 31, 2016, we were in a net borrowing position (Revolving Credit Facility). At March 31, 2016, we had cash on hand of approximately $798,000. The cash balance at March 31, 2016 was primarily cash received from the sale of certain equity by our majority-owned Polish subsidiary, PF Medical, and minor petty cash and local account balances used for miscellaneous services and supplies at our remaining subsidiaries. PF Medical is not a credit party under our Revised Loan Agreement with our lender.

Accounts Receivable, net of allowances for doubtful accounts, totaled $8,522,000 at March 31, 2016, a decrease of $1,151,000 from the December 31, 2015 balance of $9,673,000. The decrease was primarily due to lower revenue and the timing of accounts receivable collections due to the variety of payment terms provided to our customers.

Accounts Payable, totaled $5,729,000 at March 31, 2016, a decrease of $380,000 from the December 31, 2015 balance of $6,109,000. The decrease was primarily due to pay down of our accounts payable. Also, we continue to manage payment terms with our vendors to maximize our cash position throughout all segments.

Disposal/transportation accrual as of March 31, 2016, totaled $1,473,000, an increase of $366,000 over the December 31, 2015 balance of $1,107,000. Our disposal accrual can vary based on revenue mix and the timing of waste shipments for final disposal. The increase was primarily due to additional disposal costs related to our processing revenues.

We had working capital of $275,000 (which included working capital of our discontinued operations) as of March 31, 2016, as compared to working capital of $2,966,000 as of December 31, 2015. Our working capital was negatively impacted primarily by reduced revenue and the net loss we incurred during the first three months of 2016.

We entered into an Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated October 31, 2011 (“Loan Agreement”), with PNC Bank, National Association (“PNC”), acting as agent and lender. The Loan Agreement, as subsequently amended (“Amended Loan Agreement”) provided us with the following Credit Facility: (a) up to $12,000,000 revolving credit (“Revolving Credit”), subject to the amount of borrowings based on a percentage of eligible receivables (as defined) and (b) a term loan (“Term Loan”) of $16,000,000, which required monthly installments of approximately $190,000 (based on a seven-year amortization).

Under the Amended Loan Agreement, we had the option of paying an annual rate of interest due on the Revolving Credit at prime plus 2% or London Inter Bank Offer Rate (“LIBOR”) plus 3% and the Term Loan at prime plus 2.5% or LIBOR plus 3.5%.

On March 24, 2016, we entered into an amendment to our Amended Loan Agreement with our lender which provided, among other things, the following (the amendment, together with the Amended Loan Agreement is collectively known as the “Revised Loan Agreement”):

In connection with the amendment, we paid PNC a closing fee of $70,000. As a result of the amendment dated March 24, 2016, we recorded approximately $68,000 in loss on extinguishment of debt in accordance with ASC 470-50, “Debt – Modifications and Extinguishments,” which has been included in interest expense in the accompanying Consolidated Statements of Operations.

Pursuant to the amendment, we may terminate the Revised Loan Agreement upon 90 days’ prior written notice upon payment in full of its obligations under the Revised Loan Agreement. We have agreed to pay PNC 1.0% of the total financing in the event we pay off our obligations on or before March 23, 2017, .50% of the total financing if we pay off our obligations after March 23, 2017 but prior to or on March 23, 2018, and .25% of the total financing if we pays off our obligations after March 23, 2018 but prior to or on March 23, 2019. No early termination fee shall apply if we pay off its obligations after March 23, 2019.

Our Credit Facility with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our Credit Facility and terminate all commitments to extend further credit. The following table illustrates the quarterly financial covenant requirements under our Credit Facility as of March 31, 2016.

We did not meet our fixed charge coverage ratio in the first quarter of 2016. On May 23, 2016, our lender waived this non-compliance. In connection with this waiver, the Company paid PNC a fee of $5,000. We expect to meet our quarterly financial covenant requirements in each of the remaining quarters of 2016; however, if we fail to meet any of these quarterly financial covenant requirements in any of the remaining quarters in 2016 and our lender does not waive the non-compliance or revise our covenant so that we are in compliance, our lender could accelerate the repayment of borrowings under our Credit Facility. In the event that our lender accelerates the payment of our borrowings, we may not have sufficient liquidity to repay our debt under our credit facility and other indebtedness.

The Company entered into a $3,000,000 loan dated August 2, 2013 with Messrs. Robert Ferguson and William Lampson (each known as the “Lenders”). The loan is unsecured with a term of three years with interest payable at a fixed interest rate of 2.99% per annum. The loan requires monthly payments of accrued interest only during the first year of the loan with the first interest payment due September 1, 2013, and monthly payments of $125,000 in principal plus accrued interest for the second and third year of the loan. As consideration for the Company receiving the loan, the Company issued to each Lender a Warrant to purchase up to 35,000 shares of the Company’s Common at an exercise price of $2.23 per share. The Warrants expire on August 2, 2016. As further consideration for the loan, the Company also issued to each Lender 45,000 shares of the Company’s Common Stock. The fair value of the Warrants and Common Stock and the related closing fees incurred from this transaction were recorded as a debt discount, which is being amortized using the effective interest method over the term of the loan as interest expense – financing fees.

For the three months ended March 31, 2016, our purchases of capital equipment totaled approximately $9,000. These expenditures were primarily for improvements in our Treatment Segment. These capital expenditures were funded by cash from operations. We have budgeted approximately $1,200,000 for 2016 capital expenditures for our Treatment and Services Segments to maintain operations and regulatory compliance requirements. Certain of these budgeted projects may either be delayed until later years or deferred altogether. We have traditionally incurred actual capital spending totals for a given year at less than the initial budgeted amount. We plan to fund our capital expenditures from cash from operations and/or financing. The initiation and timing of projects are also determined by financing alternatives or funds available for such capital projects.

We have a number of routine operating leases, primarily related to office space rental, office equipment rental and equipment rental for contract projects as of March 31, 2016, which total approximately $1,417,000, payable as follows: $553,000 in remainder of 2016; $670,000 in 2017; with the remaining $194,000 in 2018.

From time to time, we are required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. As of March 31, 2016, the total amount of these bonds and letters of credit outstanding was approximately $1,539,000, of which the majority of the amount relates to various bonds. Our Treatment Segment facilities operate under licenses and permits that require financial assurance for closure and post-closure costs. We provide for these requirements through financial assurance policies. As of March 31, 2016, the closure and post-closure requirements for these facilities were approximately $46,824,000. We have recorded approximately $21,396,000 in a sinking fund related to these policies in other long term assets on the accompanying Consolidated Balance Sheets.

There were no significant changes in our accounting policies or critical accounting estimates that are discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Significant Customers. Our Treatment and Services Segments have significant relationships with the federal government, and continue to enter into contracts, directly as the prime contractor or indirectly for others as a subcontractor, with the federal government. The U.S Department of Energy (“DOE”) and U.S. Department of Defense (“DOD”) represent major customers for our Treatment Segment and Services Segments. The contracts that we are a party to with the federal government or with others as a subcontractor to the federal government generally provide that the government may terminate or renegotiate the contracts on 30 days notice, at the government's election. Our inability to continue under existing contracts that we have with the federal government (directly or indirectly as a subcontractor) or significant reductions in the level of governmental funding in any given year could have a material adverse impact on our operations and financial condition.

We performed services relating to waste generated by the federal government, either directly as a prime contractor or indirectly as a subcontractor to the federal government, representing approximately $6,364,000 or 63.4% of our total revenue from continuing operations during the three months ended March 31, 2016, as compared to $7,884,000 or 58.0% of our total revenue from continuing operations during the corresponding period of 2015.

We are engaged in the waste management services segment of the pollution control industry. As a participant in the on-site treatment, storage and disposal market and the off-site treatment and services market, we are subject to rigorous federal, state and local regulations. These regulations mandate strict compliance and therefore are a cost and concern to us. Because of their integral role in providing quality environmental services, we make every reasonable attempt to maintain complete compliance with these regulations; however, even with a diligent commitment, we, along with many of our competitors, may be required to pay fines for violations or investigate and potentially remediate our waste management facilities.

We routinely use third party disposal companies, who ultimately destroy or secure landfill residual materials generated at our facilities or at a client's site. In the past, numerous third party disposal sites have improperly managed waste and consequently require remedial action; consequently, any party utilizing these sites may be liable for some or all of the remedial costs. Despite our aggressive compliance and auditing procedures for disposal of wastes, we could further be notified, in the future, that we are a potentially responsible party (“PRP”) at a remedial action site, which could have a material adverse effect.

Our subsidiaries where remediation expenditures will be made are at three sites within our discontinued operations. While no assurances can be made that we will be able to do so, we expect to fund the expenses to remediate these sites from funds generated internally.

At March 31, 2016, we had total accrued environmental remediation liabilities of $900,000, of which $9,000 is recorded as a current liability. No material changes in remediation liabilities have occurred since December 31, 2015.

There are no additional material legal proceedings pending against us and/or our subsidiaries not previously reported by us in Item 3 of our Form 10-K for the year ended December 31, 2015, which is incorporated herein by reference.

There has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31, 2015.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☐ Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of Common Stock, as of the close of the latest practical date.

PART I	FINANCIAL INFORMATION		Page No.

	Item 1.	Consolidated Condensed Financial Statements (Unaudited)

		Consolidated Balance Sheets - March 31, 2016 and December 31, 2015	1

		Consolidated Statements of Operations - Three Months Ended March 31, 2016 and 2015	3

		Consolidated Statements of Comprehensive Loss - Three Months Ended March 31, 2016 and 2015	4

		Consolidated Statements of Stockholders’ Equity - Three Months Ended March 31, 2016	5

		Consolidated Statements of Cash Flows - Three Months Ended March 31, 2016 and 2015	6

		Notes to Consolidated Financial Statements	7

	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

	Item 4.	Controls and Procedures	27

PART II	OTHER INFORMATION

	Item 1.	Legal Proceedings	28

	Item 1A.	Risk Factors	28

	Item 6.	Exhibits	28

(In thousands)	2016		% Revenue		2015		% Revenue		Change			% Change
Treatment
Government waste	$	4,968		49.5	$	7,054		51.9	$	(2,086	)		(29.6	)
Hazardous/non-hazardous		1,085		10.8		997		7.3		88			8.8
Other nuclear waste		1,151		11.5		1,698		12.5		(547	)		(32.2	)
Total		7,204		71.8		9,749		71.7		(2,545	)		(26.1	)

Services
Nuclear services		2,385		23.7		3,078		22.6		(693	)		(22.5	)
Technical services		449		4.5		773		5.7		(324	)		(41.9	)
Total		2,834		28.2		3,851		28.3		(1,017	)		(26.4	)

Total	$	10,038		100.0	$	13,600		100.0	$	(3,562	)		(26.2	)

(In thousands)	2016		% Revenue		2015		% Revenue		Change
Treatment	$	7,342		101.9	$	8,514		87.3	$	(1,172	)
Services		2,662		93.9		3,608		93.7		(946	)
Total	$	10,004		99.7	$	12,122		89.1	$	(2,118	)

(In thousands)	2016		% Revenue		2015		% Revenue		Change
Administrative	$	1,188		—	$	1,349		—	$	(161	)
Treatment		1,001		13.9		956		9.8		45
Services		866		30.6		541		14.0		325
Total	$	3,055		30.4	$	2,846		20.9	$	209

●	demand for our services;
●	reductions in the level of government funding in future years;
●	ability of PF Medical to fund its R&D program;
●	reducing operating costs;
●	expect to meet our quarterly financial covenant requirements in remaining 2016;
●	may not have liquidity to repay debt if our lender accelerates payment of our borrowings;
●	our cash flows from operations and our available liquidity from our Credit Facility are sufficient to service our Treatment and Services Segments’ obligations;
●	manner in which the government will be required to spend funding to remediate federal sites;
●	reducing operating costs to bring them in line with revenue level, when necessary;
●	fund capital expenditures from cash from operations and/or financing;
●	fund remediation expenditures for sites from funds generated internally;
●	expect to receive certain large waste treatment shipments in the second and/or third quarters;
●	compliance with environmental regulations;
●	potential effect of being a PRP; and
●	potential sites for violations of environmental laws and remediation of our facilities.

●	general economic conditions;
●	material reduction in revenues;
●	ability to meet PNC covenant requirements;
●	inability to collect in a timely manner a material amount of receivables;
●	increased competitive pressures;
●	inability to maintain and obtain required permits and approvals to conduct operations;
●	public not accepting our new technology;
●	inability to develop new and existing technologies in the conduct of operations;
●	inability to maintain and obtain closure and operating insurance requirements;
●	inability to retain or renew certain required permits;
●	discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures;

●	delays at our third party disposal site can extend collection of our receivables greater than twelve months;
●	refusal of third party disposal sites to accept our waste;
●	changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such;
●	requirements to obtain permits for TSD activities or licensing requirements to handle low level radioactive materials are limited or lessened;
●	potential increases in equipment, maintenance, operating or labor costs;
●	management retention and development;
●	financial valuation of intangible assets is substantially more/less than expected;
●	the requirement to use internally generated funds for purposes not presently anticipated;
●	inability to be profitable on an annualized basis;
●	inability of the Company to maintain the listing of its Common Stock on the NASDAQ;
●	terminations of contracts with federal agencies or subcontracts involving federal agencies, or reduction in amount of waste delivered to the Company under the contracts or subcontracts;
●	renegotiation of contracts involving the federal government;
●	federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites;
●	disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment;
●	inability to raise capital on commercially reasonable terms;
●	inability to increase profitable revenue;
●	lender refuses to waive non-compliance or revises our covenant so that we are in compliance; and
●	risk factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s 2015 Form 10-K.

	Three Months Ended March 31,
Consolidated (amounts in thousands)	2016			%			2015			%
Net revenues	$	10,038			100.0		$	13,600			100.0
Cost of good sold		10,004			99.7			12,122			89.1
Gross profit		34			.3			1,478			10.9
Selling, general and administrative		3,055			30.4			2,846			20.9
Research and development		575			5.7			429			3.2
Loss on disposal of property and equipment		5			—			—			—
Loss from operations	$	(3,601	)		(35.8	)	$	(1,797	)		(13.2	)
Interest income		16			.2			8			—
Interest expense		(168	)		(1.7	)		(126	)		(.9	)
Interest expense-financing fees		(57	)		(.6	)		(58	)		(.4	)
Foreign currency loss		—			—			(5	)		—
Loss from continuing operations before taxes		(3,810	)		(37.9	)		(1,978	)		(14.5	)
Income tax expense		36			.4			36			.3
Loss from continuing operations	$	(3,846	)		(38.3	)	$	(2,014	)		(14.8	)

(In thousands)	2016
Cash provided by operating activities of continuing operations	$	251
Cash used in operating activities of discontinued operations		(184	)
Cash used in investing activities of continuing operations		(24	)
Cash used in financing activities of continuing operations		(719	)
Effect of exchange rate changes in cash		39
Decrease in cash	$	(637	)

(Dollars in thousands)	Quarterly Requirement		1st Quarter Actual
Senior Credit Facility
Fixed charge coverage ratio	1.15:1		0.91:1
Minimum tangible adjusted net worth	$	30,000	$	40,539

Item 4.	Controls and Procedures

(a)	Evaluation of disclosure controls, and procedures.

	We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management. As of the end of the period covered by this report, we carried out an evaluation with the participation of our Principal Executive Officer and Principal Financial Officer. Based on this recent assessment, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) were effective as of March 31, 2016.

(b)	Changes in internal control over financial reporting.

	There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) in the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 6.	Exhibits
(a)	Exhibits
	4.1	First Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated November 7, 2012, as incorporated by reference from Exhibit 4.1 to the Company Form 10-Q for the quarter ended September 30, 2012, filed on November 8, 2012.
	4.2	Second Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement and Waiver between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated May 9, 2013, as incorporated by reference from Exhibit 4.1 to the Company Form 10-Q for the quarter ended March 31, 2013, filed on May 10, 2013.
	4.3	Third Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated August 2, 2013, as incorporated by reference from Exhibit 4.1 to the Company Form 10-Q for the quarter ended June 30, 2013, filed on August 8, 2013.
	4.4	Fourth Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement and Waiver between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated April 14, 2014, as incorporated by reference from Exhibit 4.17 to the Company 2013 Form 10-K, filed on April 15, 2014.
	4.5	Fifth Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated July 25, 2014, as incorporated by reference from Exhibit 4.1 to the Company Form 8-K, filed on July 31, 2014.
	4.6	Sixth Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated July 25, 2014, as incorporated by reference from Exhibit 4.2 to the Company Form 8-K, filed on July 31, 2014.
	4.7	Seventh Amendment to Amended and Restated Revolving Credit, Term Loan and Security Agreement between PNC Bank, National Association and Perma-Fix Environmental Services, Inc., dated March 24, 2016, as incorporated by reference from Exhibit 4.17 to the Company 2015 Form 10-K filed on March 24, 2016.
	4.8	Waiver Letter from PNC dated May 23, 2016 for non-compliance of financial covenant.
	10.1	2016 Incentive Plan for Chief Executive Officer, effective January 1, 2016, as incorporated by reference from Exhibit 99.1 to the Company’s 8-K filed on February 10, 2016.
	10.2	2016 Incentive Plan for Chief Operating Officer, effective January 1, 2016, as incorporated by reference from Exhibit 99.2 to the Company’s 8-K filed on February 10, 2016.

	10.3		2016 Incentive Plan for Chief Financial Officer, effective January 1, 2016, as incorporated by reference from Exhibit 99.3 to the Company’s 8-K filed on February 10, 2016.
	31.1		Certification by Dr. Louis F. Centofanti, Chief Executive Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
	31.2		Certification by Ben Naccarato, Chief Financial Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
	32.1		Certification by Dr. Louis F. Centofanti, Chief Executive Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
	32.2		Certification by Ben Naccarato, Chief Financial Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
	101.INS		XBRL Instance Document*
	101.SCH		XBRL Taxonomy Extension Schema Document*
	101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document*
	101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*
	101.LAB		XBRL Taxonomy Extension Labels Linkbase Document*
	101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document*

	* Pursuant to Rule 406T of Regulation S-T, the Interactive Data File in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

		PERMA-FIX ENVIRONMENTAL SERVICES


Date: May 23, 2016	By:	/s/ Dr. Louis F. Centofanti
		Dr. Louis F. Centofanti Chairman of the Board Chief (Principal) Executive Officer


Date: May 23, 2016	By:	/s/ Ben Naccarato
		Ben Naccarato
		Chief (Principal) Financial Officer and